RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Are patients and their providers talking about long-acting injectable antiretroviral therapy? Penetration into clinical encounters at three US care sites
Christopoulos, K. A., Colasanti, J., Johnson, M. O., Tsuzuki, M. D., Erguera, X. A., Flores, R., Kerman, J., Dance, K., Sauceda, J. A., Neilands, T. B., Dilworth, S. E., Koester, K. A., Gutierrez, J., Schneider, J. A., Montgomery, E., & McNulty, M. C. (2022). Are patients and their providers talking about long-acting injectable antiretroviral therapy? Penetration into clinical encounters at three US care sites. Open Forum Infectious Diseases, 9(7). https://doi.org/10.1093/ofid/ofac293
Use of long-acting injectable antiretroviral therapy (LAI-ART) depends on patient awareness, provider discussion, and patient willingness to use. We conducted a post-visit survey with patients at three HIV clinics in San Francisco, Chicago, and Atlanta in May 2021 to assess for inequities in these early implementation phases.
